Skip to main content
SpringerLink
Log in

Modulation of Multidrug Resistance in Human Renal Cell Carcinomas

  • Conference paper
Basic and Clinical Research on Renal Cell Carcinoma

  • 50 Accesses

Abstract

Intrinsic chemoresistance has major impact on the dismal prognosis of patients with disseminated renal cell carcinoma (RCC) in the absence of reliable therapeutic alternatives [27]. P-170 glycoprotein was identified as a putative mechanism conferring drug resistance. Recently, a high expression of MDR 1 gene mRNA [13] as well as of P-170 glycoprotein [17–19] was traced in human RCCs, which may partially explain the high degree of de novo resistance. Calcium antagonists (CAs) are substances which interfere with the calcium intake at the cytoplasmatic membrane. They are mainly employed in the treatment of cardiovascular disorders such as hypertension, arrhythmia and angina pectoris. Lately, the interaction of CAs with chemotherapeutics to enhance cytotoxicity has gained particular interest. It has been shown that CAs reverse acquired resistance of experimental animal tumors [25] to some anticancer drugs and increase the life span of tumor-bearing animals compared to those merely treated with vinca alkaloids [21].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alley MC, Scudiero DA, Monks A, et al. (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589–601

    PubMed  CAS  Google Scholar 

  2. Baeyens JM (1988) Interactions between calcium channel blockers and non-cardiovascular drugs: Interactions with anticancer drugs. Pharmacol Toxicol 63: 1–7

    Article  PubMed  CAS  Google Scholar 

  3. Broxterman HJ, Pinedo HM, Kuiper CM, et al. (1989) Immunohistochemical detection of P-glycoprotein in human tumor cells with a low degree of drug resistance. Int J Cancer 43: 340–341

    Article  PubMed  CAS  Google Scholar 

  4. Cantwell B, Puamah P, Harris AL (1985) Phase I and phase II study of oral verapamil (VRP) and intravenous vindesine (VDN). Br J Cancer 52: 425

    Google Scholar 

  5. Dalton WS, Grogan TM, Meltzer PS, et al. (1989) Drug-resistance in multiple myeloma and non-Hodgkin’s Lymphoma: Detection of Pglycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415–424

    PubMed  CAS  Google Scholar 

  6. Echizen H, Brecht T, Niedergesaess S, Vogelgesang B, Eichelbaum M (1985) The effect of dextro-laevo-and racemic verapamil on atrio-ventricular conduction in humans. Am Heart J 109: 210–217

    Article  PubMed  CAS  Google Scholar 

  7. Eichelbaum M, Birkel P, Grube E, Gutgemann U, Somerogyi A (1980) Effects on P-R intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment. Klin Wochenschr 58: 919–925

    Article  PubMed  CAS  Google Scholar 

  8. Hamann SR, Blouin RA, McAllister Jr RG (1984) Clinical pharmacokinetics of verapamil. Clinical Pharmacokinetics 9: 26–41

    Article  PubMed  CAS  Google Scholar 

  9. Hermanek P (1987) UICC, TNM Classification of malignant tumors, 4th edn. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  10. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6: 65–70

    Google Scholar 

  11. Ince P, Appleton DR, Finney KJ, Sunter JP, Watson AJ (1986) Verapamil increases the sensitivity of primary human colorectal carcinoma tissue to vincristine. Br J Cancer 53: 137–139

    Article  PubMed  CAS  Google Scholar 

  12. Kaba K, Tanki E, Morimura T, Matsumoto T (1985) Potentiation of vincristine effects in human and murine gliomas by calcium channel blockers or calmodulin inhibitors. J Neurosurg 63: 905–911

    Article  PubMed  CAS  Google Scholar 

  13. Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman MM, Pastan I (1988) Measurements of multidrug resistance messenger-RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 139: 862–865

    PubMed  CAS  Google Scholar 

  14. Kanamaru H, Kakehi Y, Yoshia O, Nakanishi S, Pastan I, Gottesman MM (1989) MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst 81: 844–849

    Article  PubMed  CAS  Google Scholar 

  15. Kartner N, Evernden-Porelle D, Bradley G, Ling V (1985) Detection of P-170 glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316: 820–823

    Article  PubMed  CAS  Google Scholar 

  16. Mickisch G, Fajta S, Keilhauer G, Schlick E, Tschada R, Alken P (1990) Chemosensitivity testing of primary human renal cell carcinoma by a tetrazolium based microculture assay (MTT). Urol Res 18: 131–136

    Article  PubMed  CAS  Google Scholar 

  17. Mickisch G, Bier H, Bergler W, Bak M, Tschada R, Alken P (1990) P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. Urol Intern 45: 170–176

    Article  CAS  Google Scholar 

  18. Mickisch G, Kössig J, Keilhauer G, Schlick E, Tschada R, Alken P (1990) Effects of calcium antagonists in multidrug resistant primary human renal call carcinomas. Cancer Res 50: 3670–3674

    PubMed  CAS  Google Scholar 

  19. Mickisch G, Röhrich K, Kössig J, Forster S, Tschada R, Alken P (1990) Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. J Urol 144: 755–759

    PubMed  CAS  Google Scholar 

  20. Milroy R, Connory L, Banham F, Hutcheon D, Maclntyre D, Stack B (1987) Randomized trial of verapamil in addition to chemotherapy for small cell lung cancer. Thorax 42: 209

    Google Scholar 

  21. Morrow M, Wait RB, Rosenthal RA, Gamelli RL (1987) Verpamil enhances antitumor activity without increasing myeloid toxicity. Surgery 101: 63–65

    PubMed  CAS  Google Scholar 

  22. Ozols RF, Cunnian RE, Klecker RW, Hamilton FC, Ostchega Y, Parillo JE, Young RC (1987) Verapamil and adriamycine in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5: 641–647

    PubMed  CAS  Google Scholar 

  23. Paoletti R, Govoni S (1987) Classification of calcium antagonists: Proposal of the WHO Committee. Pharmacol Res Comm Vol. 19, 3: 195–209

    Article  CAS  Google Scholar 

  24. Simmonds AP, Moyes P, Nicol A, Davidson KG, Faichney A (1986) Enhancement of cytotoxicity of vindesine and cis-platinum for human lung tumours by the use of verapamil in vitro. Br J Cancer 54: 1015–1018

    Article  PubMed  CAS  Google Scholar 

  25. Tsuruo T (1983) Reversal of acquired resistance to vinca alcaloids and anthracycline antibiotics. Cancer Treat Rep 67: 889–894

    PubMed  CAS  Google Scholar 

  26. Tsuruo T (1988) Mechanisms of multidrug resistance and implications for therapy. Jpn J Cancer Res (Gann) 79: 285–296

    Article  CAS  Google Scholar 

  27. Vugrin D (1987) Systematic therapy of metastatic renal cell carcinoma. Sem Nephrol 7: 152–162

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA

    G. H. Mickisch

  2. Urologische Klinik, Klinikum Mannheim der Universität Heidelberg, Theodor-Kutzer-Ufer, W-6800, Mannheim, Germany

    P. M. Alken

Authors
  1. G. H. Mickisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. M. Alken
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung Urologie und Poliklinik Klinikum, Ruprecht-Karls-Universität, Im Neuenheimer Feld 110, W-6900, Heidelberg, Germany

    Gerd Staehler  & Sigmund Pomer  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Mickisch, G.H., Alken, P.M. (1992). Modulation of Multidrug Resistance in Human Renal Cell Carcinomas. In: Staehler, G., Pomer, S. (eds) Basic and Clinical Research on Renal Cell Carcinoma. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76863-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76863-7_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-76865-1

  • Online ISBN: 978-3-642-76863-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation